E-LIB Suche - Ergebnisse für: Schmierer, K.

1

Organic solvents and Multiple Sclerosis: the doubled risk d..:

Seaton, A ; Baker, D ; Hedstrom, A K..
Occupational Medicine. 73 (2023) 6 - p. 300-303 , 2023

2

Anaesthetic management of people with multiple sclerosis:

Dubuisson, N. ; de Maere d'Aertrijcke, O. ; Marta, M....
Multiple Sclerosis and Related Disorders. 80 (2023) - p. 105045 , 2023

Link: https://doi.org/10.1016/..

3

Did it hurt? COVID-19 vaccination experience in people with..:

Allen-Philbey, K. ; Stennett, A. ; Begum, T....
Multiple Sclerosis and Related Disorders. 65 (2022) - p. 104022 , 2022

Link: https://doi.org/10.1016/..

4

Retinal vasculopathy with cerebral leukoencephalopathy and ..:

Redha, I ; Lees, M ; Campbell, D...
Neuroimmunology Reports. 2 (2022) - p. 100132 , 2022

Link: https://doi.org/10.1016/..

5

EE257 Cost-Effectiveness Analysis of AI-Assisted Radiologic..:

Esposito, G ; Sima, D ; Smeets, D.
Value in Health. 25 (2022) 12 - p. S104 , 2022

Link: https://doi.org/10.1016/..

6

MS can be considered a primary progressive disease in all c..:

Schmierer, K ; Giovannoni, G
Multiple Sclerosis Journal. 27 (2021) 7 - p. 1006-1007 , 2021

Link: https://doi.org/10.1177/..

7

Experience with the COVID-19 AstraZeneca vaccination in peo..:

Allen-Philbey, K. ; Stennett, A. ; Begum, T....
Multiple Sclerosis and Related Disorders. 52 (2021) - p. 103028 , 2021

Link: https://doi.org/10.1016/..

8

Severe lymphopenia after subcutaneous cladribine in a patie..:

Mateo-Casas, M. ; Reyes, S. ; De Trane, S....
eNeurologicalSci. 21 (2020) - p. 100279 , 2020

Link: https://doi.org/10.1016/..

9

COVID-19 vaccine-readiness for anti-CD20-depleting therapy ..:

Baker, D ; Roberts, C A K ; Pryce, G...
Clinical and Experimental Immunology. 202 (2020) 2 - p. 149-161 , 2020

Link: https://doi.org/10.1111/..

10

Severe skin reactions associated with cladribine in people ..:

Mateo-Casas, M ; Reyes, S ; O'Toole, EA...
Multiple Sclerosis and Related Disorders. 43 (2020) - p. 102140 , 2020

Link: https://doi.org/10.1016/..

11

Patient perspective on decisions to switch disease-modifyin..:

Manzano, A. ; Eskyté, I. ; Ford, H.L....
Multiple Sclerosis and Related Disorders. 46 (2020) - p. 102507 , 2020

Link: https://doi.org/10.1016/..

12

Failed B cell survival factor trials support the importance..:

Baker, D. ; Pryce, G. ; James, L. K...
European Journal of Neurology. 27 (2019) 2 - p. 221-228 , 2019

Link: https://doi.org/10.1111/..

13

Glatiramer acetate as a clinically and cost-effective treat..:

Giovannoni, G ; Brex, PA ; Dhiraj, D...
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 5 (2019) 4 - p. 205521731989310 , 2019

Link: https://doi.org/10.1177/..

14

Quantifying multiple sclerosis pathology in post mortem spi..:

Schmierer, K. ; McDowell, A. ; Petrova, N....
NeuroImage. 182 (2018) - p. 251-258 , 2018

Link: https://doi.org/10.1016/..

15

Validating the portal population of the United Kingdom Mult..:

Middleton, R.M. ; Rodgers, W.J. ; Chataway, J....
Multiple Sclerosis and Related Disorders. 24 (2018) - p. 3-10 , 2018

Link: https://doi.org/10.1016/..